Several other label expansion studies on Imfinzi are currently underway, targeting other cancer indications. Imfinzi remains ...

AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.

AstraZeneca's Imfinzi (durvalumab)has been recommended for approval in the European Union (EU) for the treatment of adult patientswith resectable muscle-invasive bladder cancer (MIBC)in ...

Imfinzi plus BCG induction and maintenance therapy showed a statistically and clinically meaningful improvement in DFS for some with bladder cancer.

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

AstraZeneca’s (AZN) Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell lun ...

Recommendation based on AEGEAN Phase III trial results which showed Imfinzi reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone AstraZeneca’s Imfinzi ...

IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with resectable non-small cell lung cancer (NSCLC). This decision is based on ...

The FDA approves AZN's Imfinzi for treating patients with limited-stage small-cell lung cancer based on phase III ADRIATIC study data.

AstraZeneca AZN announced that the FDA expanded the label of its blockbuster cancer drug Imfinzi for a fourth indication in lung cancer.

AstraZeneca's (AZN) receives FDA approval to use its anti-PD-L1 immunotherapy for another indication in lung cancer, Read more here.